|Bid||3.9200 x 900|
|Ask||4.0200 x 1100|
|Day's Range||3.9100 - 4.0900|
|52 Week Range||3.7100 - 21.5000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced receipt of written feedback to its Type B Pre-IND (Pre-Investigational New Drug application) meeting request from the U.S. Food and Drug Administration (FDA) that is in general agreement with the Company's planned clinical development of AS1411, a nucleolin-targeting DNA aptamer drug candidate, for the treatment of COVID-19.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces it has entered into an agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd, of Suzhou, China to develop, manufacture and sell new generations of diagnostic test systems based on Qualigen's core FastPack® "laboratory in a pouch" technology. In addition, Yi Xin Zhen Duan Jishu (Yi Xin) will have the rights to manufacture and sell Qualigen's current generations of rapid point-of-care FastPack diagnostic products in China.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announces it has entered into an amended Sponsored Research Agreement with the University of Louisville (UofL) to advance development of Qualigen's anticancer drug candidate AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin).